insights_auto
Perché BT3 è in rialzo 2,14%?
Approfondiscichevron_right
BT3:FRA
BioTime
0,76 €
arrow_upward
+2,14%(+0,016) 1G
20 nov, 22:00:00 GMT+1 · EUR
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per BT3 in corso…
Apertura
0,76 €
Massimo
0,76 €
Minimo
0,76 €
Cap. mercato
195,26 Mln
Vol. medio
100,00
Volume
0,00
Max 52 sett.
1,68 €
Min 52 sett.
0,72 €
N. di dipendenti
75
Apertura
0,76 €
Massimo
0,76 €
Minimo
0,76 €
Cap. mercato
195,26 Mln
Vol. medio
100,00
Volume
0,00
Max 52 sett.
1,68 €
Min 52 sett.
0,72 €
N. di dipendenti
75
Articoli giornalistici
Da fonti web e partner giornalistici
WSJ
·
1 giorno fa
Dow, S&P 500 Poised to Close at a Correction
Yahoo Finance
·
7 ore fa
In the Last Tech Bust, the S&P 500 Lost Money for a Decade. History Says Stocks With the Highest Yields Gained 5.4% a Year.
Beinsure
·
12 ore fa
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
24/7 Wall St.
·
9 ore fa
The S&P 500 Is Now Below Every Wall Street Year-End Target for 2026
Profilo
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Informazioni su BioTime